SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of layoffs in India and the Philippines, with termination notices citing a scaled-down business assignment, have sparked concern that Innodata may have lost or reduced a major client project. Traders are divided between that revenue-risk interpretation and the view that the cuts reflect efficiency or a shift to contract workers, with the uncertainty weighing on shares ahead of Q3 results.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

A recent rebound that held near breakout levels has prompted bullish swing-trade setups and call buying ahead of earnings. Traders are watching for follow-through, while some remain cautious about weak housing demand and interest-rate sensitivity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Attention centers on ImmunityBios upcoming QUILT-2.005 Phase 3 topline readout of ANKTIVA plus BCG for first-line bladder cancer; the company has completed the database lock and says an sBLA filing is on track for Q4. Traders are largely optimistic about the potential label expansion, while also watching Q3 results and debating whether the clinical and commercial momentum will justify the bullish expectations.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is drawing attention after a sharp precious-metals selloff and a reported 52-week low, with traders citing Fed rate-hike expectations and possible forced liquidation as pressures. The community is split between calling gold a failed safe haven and viewing the decline as a buying opportunity, with some watching for support or a rebound.

World Liberty Financial (WLFI) is a cryptocurrency launched in 2025and operates on the Ethereum platform. World Liberty Financial has a current supply of 100,000,000,000 with 31,779,991,497 in circulation. The last known price of World Liberty Financial is 0.05007445 USD and is up 0.02 over the last 24 hours. It is currently trading on 491 active market(s) with $20,910,403.62 traded over the last 24 hours. More information can be found at https://www.worldlibertyfinancial.com/.

WorldFinancial

WLFI discussion centers on its prolonged weakness and concerns that Trump-family crypto monetization and potential token sales are weighing on sentiment. Bulls counter that a bank charter and USD1-related utility could support a rebound, though those catalysts are discussed largely as expectations, while skeptics see no near-term support.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is drawing attention after a sharp gain alongside elevated volatility and unusually heavy call activity. Traders are split between treating the move as a hedge against market risk and expecting the volatility spike to fade, citing the funds tendency to decay over time.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Traders are framing disruptions to Qatari and other Middle Eastern LNG supply, including shipping risks around the Strait of Hormuz, as a potential tailwind for U.S. exporters and future contracting leverage at NextDecades Rio Grande project. Skeptics note that NEXT has not yet begun production and remains exposed to construction, financing, and execution risks ahead of planned first LNG output in 2027.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is drawing attention after a steep selloff as investors await Q3 results to gauge whether Auvelitys Alzheimers-agitation launch is translating into paid prescriptions and whether commercial spending is delaying profitability. Some traders believe sampling and long-term-care channels understate demand, while others point to sluggish visible prescription growth, managements silence and cash-burn concerns.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladocs Q3 update sparked a sharp rally as traders focused on stronger profitability and cash generation, while revenue remained under pressure and BetterHelp continued to weigh on the growth outlook. Bulls are debating whether the results mark a turnaround and could pressure short sellers; skeptics see unresolved growth and execution risks.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes quarterly results beat expectations and included a modest outlook increase, but the shares sold off sharply and reached a 52-week low. Traders disagree over whether the decline is excessive given the companys cash position and buyback, or justified by weak growth, reliance on an R&D grant, and concerns about competition and demand for higher-end driver-assistance systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

First Solar's Q3 Earnings Beat Estimates, Revenues Decrease Y/Y

FSLR's Q3 2026 earnings beat estimates by 14.2%, despite a 23% revenue decline, while the company lowered its sales and shipment outlook for 2026.

Array Technologies, Inc. (ARRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Array Technologies (ARRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

First Solar to Release Q3 Earnings: Here's What to Expect 

FSLR faces strong solar demand ahead of Q3 results, but trade policy uncertainty and underutilized overseas plants could weigh on performance.

Array Technologies, Inc. (ARRY) Stock Drops Despite Market Gains: Important Facts to Note

In the closing of the recent trading day, Array Technologies, Inc. (ARRY) stood at $3.15, denoting a -1.25% move from the preceding trading day.

Enphase Energy is Set to Report Q3 Earnings: What's in Store? 

ENPH gears up for Q3 earnings, with improving solar demand and new product launches offering support amid declining estimates and tariff pressures.

Array Technologies, Inc. (ARRY) Rises Higher Than Market: Key Facts

In the closing of the recent trading day, Array Technologies, Inc. (ARRY) stood at $3.33, denoting a +2.15% move from the preceding trading day.

Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure  

Equity

Growth prospects, business challenges, legal changes, and rising competition from SpaceX shaped Wall Street activity this week.

Array Technologies, Inc. (ARRY) Suffers a Larger Drop Than the General Market: Key Insights

Array Technologies, Inc. (ARRY) concluded the recent trading session at $3.38, signifying a -5.32% move from its prior day's close.

Is NXT Worth Buying as Growth Broadens but Execution Risks Build?

Nextpower's expanding solar platform and $5.5 billion-plus backlog fuel growth prospects, but rising costs, U.S. concentration and valuation pose risks.

Implied Volatility Surging for Array Technologies Stock Options

Investors need to pay close attention to ARRY stock based on the movements in the options market lately. 

Array Technologies, Inc. manufactures ground-mounting systems used in solar energy projects. The company sells its products to engineering, procurement and construction firms that build solar energy projects and to large solar developers, independent power producers and utilities, master supply agreements or multi-year procurement contracts. It has offices in Europe, Central America, and Australia. The company's products include DuraTrack and SmarTrack. Array Technologies was founded by Ronald P. Corio in 1989 and is headquartered in Albuquerque, NM.

Array Technologies Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Crocs stock rose 8.5% this week as Barclays upgraded it to ‘Overweight’ from ‘Equal Weight’.</li><li>Liquidia stock surged 27% this week, its strongest since May, after settling six lawsuits with United Therapeutics.&nbsp;</li><li>Albertsons faced downgrades after its Q2 results, as concerns grew over operational hurdles.&nbsp;</li></ul><p>Wall Street analysts warmed to Crocs Inc. (CROX) and Liquidia Corp. (LQDA) on growth potential and easing legal risks, while Albertsons Companies (ACI) faced downgrades from three firms. Meanwhile, SpaceX’s growing ambitions rattled sentiment around AT&amp;T (T) and AST SpaceMobile (ASTS), triggering concerns over telecom competition and satellite launch plans.&nbsp;</p><h2 class="st-heading-2">Product Momentum Supports Crocs Upgrade</h2><p><a href="https://stocktwits.com/symbol/CROX">Crocs stock</a> gained 8.5% this week as the company received an upgrade to ‘Overweight’ from ‘Equal Weight’ at Barclays, which increased its price target to $139 from $118. The firm sees a clearer route to expansion over the coming years.</p><p>Barclays believes improving conditions across the business could help Crocs move past a period of uneven performance. Although its North American operations continue to face short-term challenges, investments in new products, additional categories, and brand development appear to be supporting demand. International operations are already generating sales growth.</p><p>Last month, Crocs CFO Patraic Reagan said footwear demand naturally rises and falls every few years, but Crocs is reducing its reliance on classic clogs by expanding into sandals, ballet flats, recovery shoes and other styles. Its sandal business generates nearly $500 million annually. The company is also expanding HEYDUDE into products for activities like boating, fishing and work.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20261016_043744873_5d87402f2b.png" alt="koyfin_20261016_043744873.png" width="2400" height="1240"></figure><h2 class="st-heading-2">Legal Settlement Lifts Liquidia Outlook</h2><p><a href="https://stocktwits.com/symbol/LQDA">Liquidia stock</a> has climbed 27% and is on track for its best week since May after it won upgrades from LifeSci Capital and BTIG after reaching an agreement with United Therapeutics Corp. (UTHR) that resolves six outstanding lawsuits between the companies.</p><p>LifeSci Capital analyst Gaurav Maini raised Liquidia to ‘Outperform’ from ‘Market Perform’ and established a $59 price target. The firm believes the agreement removes a major source of uncertainty, allowing Yutrepia to remain available for pulmonary arterial hypertension while removing its use for pulmonary hypertension associated with interstitial lung disease from the label. The settlement could also make Liquidia more attractive to potential strategic partners or buyers.</p><p>Separately, BTIG moved to ‘Buy’ from ‘Neutral’ and set a $70 target. The firm viewed the settlement terms more positively than it had expected before the announcement.</p><h2 class="st-heading-2">Array Technologies Draws Contrarian Interest</h2><p><a href="https://stocktwits.com/symbol/ARRY">Array Technologies stock</a> was upgraded to ‘Outperform’ from ‘Neutral’ by Mizuho, even as the firm cut its price target to $5 from $7. The stock has dropped 61% this year, but the analyst sees room for gains compared with the risk of further losses.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20261016_044341010_b622791540.png" alt="koyfin_20261016_044341010.png" width="2400" height="1240"></figure><p>Mizuho believes investors are too worried about weaker demand and the company’s need for cash. The firm expects business to improve in 2027, supported by existing orders and acquisitions that could help cut costs and improve efficiency. It also expects sales and profit margins to outperform market forecasts.&nbsp;</p><h2 class="st-heading-2">Albertsons Faces Multiple Analyst Downgrades</h2><p><a href="https://stocktwits.com/symbol/ACI">Albertsons Companies stock</a> faced three analyst downgrades this week after its fiscal second-quarter results, as concerns grew over its business plan and financial outlook.</p><p>JPMorgan lowered its rating to ‘Neutral’ from ‘Overweight’ but kept its $14 price target unchanged. Although Albertsons shares are cheaper than those of many U.S. grocery rivals, the firm believes ongoing business challenges and weaker-than-expected cost-cutting efforts may explain the lower valuation.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20261016_044948856_fe781ba6d5.png" alt="koyfin_20261016_044948856.png" width="2400" height="1240"></figure><p>Goldman Sachs and Bank of America downgraded Albertsons and cut their price targets, citing uncertainty about the company’s growth plans and a suspended 2026 forecast. The analysts expect the stock to remain in a narrow range until management provides more details on its growth plans after completing a business review by spring 2027.</p><h2 class="st-heading-2">SpaceX Competition Clouds AT&amp;T,&nbsp; AST SpaceMobile Prospects</h2><p><a href="https://stocktwits.com/symbol/T">AT&amp;T stock</a> was downgraded to ‘Market Perform’ from ‘Outperform’ by Bernstein, which lowered its price target to $24 from $25. The analyst sees growing competition from SpaceX across broadband and wireless services as an additional challenge for established telecom providers.</p><p>Bernstein also cited recent pricing decisions by incumbent carriers and the possibility of seasonal weakness in the fourth quarter.&nbsp;<a href="https://stocktwits.com/symbol/ASTS">AST SpaceMobile stock</a> was downgraded to ‘Neutral’ from ‘Overweight’ at Piper Sandler, which cut its price target to $54 from $98. The firm has less confidence in the company's planned satellite deployment pace in 2026 and 2027.</p><p>SpaceX’s $8 billion purchase of mobile spectrum last week has raised concerns about competition in satellite-based phone services. Piper warned that SpaceX could limit rocket launch access for partners like AST SpaceMobile, delaying the company’s satellite deployment plans.&nbsp;</p><p>So far this year, CROX and LQDA have gained 0.8% and 45%, respectively, while ARRY, ACI, T and ASTS stocks have declined between 5% and 61%.&nbsp;</p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aa-stock-rises-overnight-alcoa-ceo-bets-on-massena-east-for-cash-pump-as-alumina-market-tightens/cZx0w5uRBs2">AA Stock Rises Overnight: Alcoa CEO Bets On Massena East For Cash Pump As Alumina Market Tightens</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

A Crocs logo sign is seen in New York City, United States.

Wall Street analysts warmed to Crocs Inc. (CROX) and Liquidia Corp. (LQDA) on growth potential and easing legal risks, while Albertsons Companies (ACI) faced downgrades from three firms. Meanwhile, SpaceX’s growing ambitions rattled sentiment around AT&T 

Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure

Albertsons Companies Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

Crocs Inc

Liquidia Corp

SpaceX

AT&T Inc

United Therapeutics Corp

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.39
Prev Close	$3.56
Open	$3.41
Dividend Yield	0.00%
50-Day Moving Average	$4.00
Beta	1.56
Avg. Volume	6.44M
PE Ratio	-3.49

52-Week High	$12.23
52-Week Low	$3.09
Market Capitalization	$522.09M
EPS (Annual)	-$0.7345
Price to Book	-2.58
Revenue Per Employee	$1.07M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARRY Fundamentals